In this regard, we conjecture that the JAK2-V617F mutation leads to activation of the JAK2-STAT5 pathway, which in turn increases eosinophilia and causes vascular damage as another risk factor for the development of BCS in this patient. The gene discussed is JAK2; the disease is Increased total eosinophil count.